LivaNova PLC (LIVN) Price Target Analysis
Updated Jul 2, 2026
Analyst Rating: Buy
Based on 15 analysts2.6% Above Target
LIVN trades 2.6% above Wall Street's consensus target of $81.43.
Current Price$83.62
Average Target$81.43
Target
Current
Low$66.00
Median$81.00
High$92.00
Analyst Target Range
Forward P/E19.7x
(Fair)
PEG Ratio—
Implied Growth+121.7%
(High Growth)
Analyst Spread31.9%
(Moderate)
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Consensus Scenario Assumptions
The base valuation assumes LIVN achieves its forward estimates and maintains a stable P/E multiple of 19.7x. This scenario reflects the blended consensus of 15 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
LIVN Price Target Analysis
Updated July 6, 2026As of July 6, 2026, LivaNova PLC (LIVN) has a Wall Street consensus price target of $81.43, based on estimates from 15 covering analysts. With the stock currently trading at $83.62, this represents a potential downside of -2.6%. The company has a market capitalization of $4.59B.
Analyst price targets range from a low of $66.00 to a high of $92.00, representing a 32% spread in expectations. The median target of $81.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 11 analysts rating the stock as a Buy or Strong Buy,3 rating it Hold, and 1 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, LIVN trades at a trailing P/E of -18.8x and forward P/E of 19.7x. Analysts expect EPS to grow +121.7% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside
+34.2%
Industry Consensus
Avg Forward P/E
20.9x
(Fair)
Peers with Coverage
10 / 10
Active Analyst Tracking
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 NVCRNovoCure Limited | $2.0B | $17.20 | $33.00 | +91.9% | Buy | — | 15 |
 INVAInnoviva, Inc. | $1.6B | $22.31 | $37.00 | +65.8% | Buy | 6.3x | 10 |
 GKOSGlaukos Corporation | $8.7B | $148.34 | $153.33 | +3.4% | Buy | — | 24 |
 MDTMedtronic plc | $106.8B | $83.19 | $95.80 | +15.2% | Buy | 14.0x | 51 |
 ABTAbbott Laboratories | $166.2B | $95.39 | $125.62 | +31.7% | Buy | 17.4x | 41 |
 BSXBoston Scientific Corporation | $67.1B | $45.14 | $82.40 | +82.5% | Buy | 13.4x | 44 |
 SYKStryker Corporation | $120.1B | $313.38 | $387.46 | +23.6% | Buy | 20.9x | 51 |
 ELMDElectromed, Inc. | $376M | $45.43 | $38.00 | -16.4% | Buy | 37.3x | 5 |
 HOLXHologic, Inc. | $17.0B | $76.01 | $78.69 | +3.5% | Hold | 17.2x | 42 |
 ISRGIntuitive Surgical, Inc. | $150.9B | $426.01 | $597.78 | +40.3% | Buy | 40.8x | 55 |
LIVN — Frequently Asked Questions
Quick answers to the most common questions about buying LIVN stock.
What is the LIVN stock price target for 2026?
Wall Street's consensus price target for LIVN is $81.43, -2.6% from its current price of $83.62. The below-market target from 15 analysts suggests limited near-term appreciation.
Is LIVN a buy, sell, or hold?
LIVN has a consensus rating of "Buy" based on 15 Wall Street analysts. The rating breakdown is predominantly bullish, with 11 Buy/Strong Buy ratings. The consensus 12-month price target of $81.43 implies -2.6% downside from current levels.
Is LIVN stock overvalued or undervalued?
With a forward P/E of 19.679x, LIVN trades at a relatively low valuation. The consensus target of $81.43 implies -2.6% move, suggesting the market may be pricing in risks.
How high can LIVN stock go?
The most bullish Wall Street analyst has a price target of $92 for LIVN, while the most conservative target is $66. The consensus of $81.43 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover LIVN stock?
LIVN is well covered by analysts, with 15 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 11 have Buy ratings, 3 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the LIVN stock forecast?
The 12-month LIVN stock forecast based on 15 Wall Street analysts shows a consensus price target of $81.43, with estimates ranging from $66 (bear case) to $92 (bull case). The median consensus rating is "Buy".
What is LIVN's forward P/E ratio?
LIVN trades at a forward P/E ratio of 19.7x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy LIVN stock?
Analysts are cautious on LIVN, with 1 Sell ratings and a price target of $81.43 (-2.6% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do LIVN price targets vary so much?
LIVN analyst price targets range from $66 to $92, a 32% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $81.43 consensus represents the middle ground.
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare